Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > AVTX Avalo Therapeutics > Detailed Quotes

AVTX Avalo Therapeutics

Watchlist
5.440
-0.070-1.27%
Close  12/06 16:00 ET
High
5.664
Open
5.463
Turnover
37.88K
Low
5.320
Pre Close
5.510
Volume
6.90K
Market Cap
51.21M
P/E(TTM)
Loss
52wk High
22.800
Shares
9.41M
P/E(Static)
Loss
52wk Low
2.423
Float Cap
17.98M
Bid/Ask %
33.33%
Historical High
91.799
Shs Float
3.30M
Volume Ratio
1.02
Historical Low
2.412
Dividend TTM
--
Div Yield TTM
--
P/B
-25.30
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.21%
Amplitude
6.24%
Avg Price
5.492
Lot Size
1
Float Cap
17.98M
Bid/Ask %
33.33%
Historical High
91.799
Shs Float
3.30M
Volume Ratio
1.02
Historical Low
2.412
Dividend TTM
--
P/B
-25.30
Dividend LFY
--
Turnover Ratio
0.21%
Amplitude
6.24%
Avg Price
5.492
Lot Size
1
Price Forecast

News

Comment

No Data

Company Overview More
Avalo Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.
CEO: Dr. Garry A. Neil, M.D.
Market: NASDAQ
Listing Date: 11/13/2015
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist